Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KRONOS BIO, INC. : Other Events (form 8-K)

11/29/2021 | 08:04am EST

Item 8.01 Other Events.

On November 29, 2021, Kronos Bio, Inc. (the "Company") announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the Company's internally discovered, highly selective, oral cyclin dependent kinase 9 ("CDK9") inhibitor being developed to treat MYC-amplified solid tumors.

An interim analysis of the ongoing dose escalation stage of the trial (data cut-off October 29) demonstrated a differentiated pharmacokinetic ("PK") profile and evidence of target engagement for KB-0742. The PK analysis showed oral bioavailability and dose-proportional exposure across the first three dose levels, with low to moderate variability between patients. Among the 12 patients treated in the trial, KB-0742 had a terminal half-life of 24 hours, with approximately 2 to 2.5-fold accumulation between Day 1 and Day 10. This long plasma half-life supports the Company's approach to defining a therapeutic window for CDK9 inhibition. Proprietary target engagement assays developed and prospectively validated at the Company demonstrated dose-dependent reduction of phosphorylated of Ser2 on RNA Polymerase II, a direct substrate target of CDK9, as well as reduced expression of CDK9-dependent genes in peripheral blood mononuclear cells of patients at all three dose levels. Consistent with the Company's preclinical models, further dose escalation is required to reach desired levels of CDK9 inhibition. The safety profile thus far is consistent with what is seen among heavily pretreated patients with cancer in similar studies.

The trial consists of two stages. The first and ongoing stage is assessing the safety, PK and PD profile of KB-0742. This dose escalation stage is designed to define the recommended Phase 2 dose and schedule ("RP2D") as efficiently as possible and is, therefore, not specifically enrolling patients based on MYC status. The second stage will enroll patients with MYC-amplified or over-expressing tumors as well as other transcriptionally addicted tumor types to assess the anti-tumor activity of KB-0742 at the RP2D. The Company is continuing to enroll patients in the dose-escalation stage of the study and anticipates presenting data from the study at a future medical conference.

Forward-Looking Statements

Statements in this report that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This report, in some cases, uses terms such as "will," "anticipates" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plan to continue enrolling patients in the Phase 1/2 clinical trial of KB-0742? the design of such Phase 1/2 clinical trial and expected future progress and activities, including in relation to the second stage of the trial? our expectation to present data from such Phase 1/2 clinical trial at a future medical conference? and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether we will be able to complete ongoing enrollment for the Phase 1/2 clinical trial of KB-0742 on the timeline expected, or at all, including due to risks associated with the COVID-19 pandemic; risks inherent in the clinical development of novel therapeutics? risks related to our lack of experience as a company in conducting clinical trials? and risks associated with the sufficiency of our cash resources and need for additional capital. These and other risks and uncertainties are described in greater detail in the Company's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the SEC on November 9, 2021. Any forward-looking statements that are made in this report speak only as of the date of this report and are based on management's assumptions and estimates as of such date. Except as required by law, the Company assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about KRONOS BIO, INC.
01/14INSIDER BUY : Allogene Therapeutics
MT
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to NASDAQ Biotechnology Index
CI
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to S&P Biotechnology Select Industry Index
CI
2021Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Ent..
CI
2021Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -144 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -3,43x
Yield 2021 -
Capitalization 525 M 525 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 95
Free-Float 83,1%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,32 $
Average target price 40,25 $
Spread / Average Target 332%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-31.42%564
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381